StockData

Cytokinetics vs Gossamer Bio

CYTK and GOSS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYTK and GOSS compare

Gossamer Bio is the larger company, worth 811 times as much as Cytokinetics ($5.4B against $6.6M).

Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −21.1% for Cytokinetics).

Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −1321% at Cytokinetics.

Cytokinetics scores higher on the StockData Score (4 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYTKGOSS
Size and price
Market cap$6.6M$5.4B
Share price$53.17$10.98
Change, 1 year−18.8%−94.5%
Change, 5 years36.2%−98.7%
Beta (5Y)1.082.34
Employees673161
StockData Score
Total score4 (better)1
Valuation score1 (better)0
Growth score11
Performance score1 (better)0
Health score1 (better)0
Dividend score00
Valuation
P/S0.1× (better)101×
FCF yield−8776%−3.0% (better)
Growth
Revenue growth (TTM)−21.1%32.4% (better)
Revenue growth, 5Y average9.5%–
Profitability
Operating margin−1046%−312% (better)
Net margin−1321%−235% (better)
FCF margin−858%−305% (better)
Financial health
Interest coverage–−15.2×
Current ratio6.66 (better)0.53
Altman Z-score−3.37 (better)−15.36
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions115%0.98%
Held by insiders0.68%2.8%
Insider net buying, 12 months−$51.5M–
Superinvestors holding–1
Short interest, % of float13.0%0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.